and received his M.D. from the University of Pennsylvania School of Medicine. About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology,

and 4.2%). Based on Merck's statement of cash flows, I would not be surprised if the company increased dividends soon. In fact, Merck had nearly $11 billion of operating cash inflow in 2010 and $9.15 billion of operating cash inflow in the first three quarters

both chronic hepatitis C virus and HIV by potentially reducing the effectiveness of these medicines when co-administered," Merck said in a February 6 letter to healthcare professionals. Victrelis, approved last May, attacks the hepatitis C virus that over

on the sidelines of Bio-Asia 2012, which began here on Thursday. He said Merck, at present the second largest pharmaceutical company in the world, had great plans for emerging markets with a strategy to bring out innovative products. With 18 per cent of the

Monetary Fund and the European Union to recover its debts. Bruno Strigini, president of Europe/Canada at US drug maker Merck, said that of the €12bn owed to the pharma industry in Europe – debts that are more than 30 days old – €6bn is outstanding in Spain.

came out with a stellar earnings report. It still looks like a value at these levels and if anything, is gaining momentum. The company is raising its dividend 19% to $1.55 a shareEarnings increased 26% year over year and sales rose 9% over the same time spanLorillard

13.1%. Unfortunately, a look at the most recent numbers doesn't tell us much about where Merck has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units

faces $6 billion in pharmaceutical debt and owes about $4 billion for medical devices, said Bruno Strigini, Merck & Co.’s president of Europe and Canada. Industry representatives are in talks with the Spanish government over the debt, and international intervention

Ph.D., has decided to retire from its board of directors, effective today. Dr. Shenk is leaving the board to focus on the new company he is forming to commercialize discoveries made in his Princeton University laboratory in the area of antiviral therapeutics.

any other large-scale structure of its type had been delivered. Although its analysis gave little hope of beating the target, Merck's Global Engineering Group organized the project as an integrated partnership in a "hypertracked" engineer-procure-construction